Biolife Sciences Stock Price To Book
| BLFE Stock | USD 0.0001 0.00 0.00% |
BioLife Sciences fundamentals help investors to digest information that contributes to BioLife Sciences' financial success or failures. It also enables traders to predict the movement of BioLife Pink Sheet. The fundamental analysis module provides a way to measure BioLife Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLife Sciences pink sheet.
BioLife |
BioLife Sciences Company Price To Book Analysis
BioLife Sciences' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, BioLife Sciences has a Price To Book of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Instruments & Supplies industry. The price to book for all United States stocks is 100.0% higher than that of the company.
BioLife Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLife Sciences' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioLife Sciences could also be used in its relative valuation, which is a method of valuing BioLife Sciences by comparing valuation metrics of similar companies.BioLife Sciences is currently under evaluation in price to book category among its peers.
BioLife Fundamentals
| Current Valuation | 1.01 M | |||
| Price To Sales | 0 X | |||
| Net Income | (456.87 K) | |||
| Cash And Equivalents | 15.62 K | |||
| Total Debt | 398 K | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (106.55 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 0.0763 | |||
| Market Capitalization | 11.45 K |
About BioLife Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLife Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLife Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLife Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLife Pink Sheet
BioLife Sciences financial ratios help investors to determine whether BioLife Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLife with respect to the benefits of owning BioLife Sciences security.